Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
367 USD | +0.39% | +1.60% | +11.14% |
Nov. 17 | JPMorgan Chase Raises Price Target on Molina Healthcare to $392 From $367, Maintains Overweight Rating | MT |
Nov. 17 | Investors see life through rose-colored glasses | ![]() |
Financials (USD)
Sales 2023 * | 33.35B | Sales 2024 * | 38.15B | Capitalization | 21.4B |
---|---|---|---|---|---|
Net income 2023 * | 1.12B | Net income 2024 * | 1.3B | EV / Sales 2023 * | 0,54x |
Net cash position 2023 * | 3.24B | Net cash position 2024 * | 4.52B | EV / Sales 2024 * | 0,44x |
P/E ratio 2023 * | 19,0x | P/E ratio 2024 * | 16,3x | Employees | 15,000 |
Yield 2023 * | - | Yield 2024 * | - | Free-Float | 98.87% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
1 day | +0.39% | ||
1 week | +1.60% | ||
Current month | +0.39% | ||
1 month | +8.76% | ||
3 months | +17.36% | ||
6 months | +25.20% | ||
Current year | +11.14% |
1 week
350.49
370.39

1 month
346.25
372.00

Current year
256.19
372.00

1 year
256.19
372.00

3 years
196.08
374.00

5 years
102.85
374.00

10 years
31.60
374.00

Managers | Title | Age | Since |
---|---|---|---|
Joseph Zubretsky
CEO | Chief Executive Officer | 66 | 2017 |
Mark Keim
DFI | Director of Finance/CFO | 57 | 2017 |
Jason Dees
CTO | Chief Tech/Sci/R&D Officer | - | 2018 |
Members of the board | Title | Age | Since |
---|---|---|---|
Barbara Brasier
BRD | Director/Board Member | 65 | 2019 |
Daniel Cooperman
BRD | Director/Board Member | 72 | 2013 |
Richard Zoretic
BRD | Director/Board Member | 64 | 2017 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.93% | 34 M€ | +17.11% | - | |
3.81% | 821 M€ | -3.73% | - | |
2.91% | 158 M€ | +14.10% | - | |
2.60% | 7 M€ | -9.60% |
Date | Price | Change | Volume |
---|---|---|---|
23-12-05 | 367 | +0.39% | 277,339 |
23-12-04 | 365.56 | +0.77% | 261,558 |
23-12-01 | 362.76 | -0.77% | 340,842 |
23-11-30 | 365.56 | +4.20% | 658,620 |
23-11-29 | 350.82 | -2.88% | 590,806 |
Delayed Quote Nyse, December 05, 2023 at 04:00 pm EST
More quotes
Molina Healthcare, Inc. specializes in the provision of health care services managed within the Medicaid and Medicare health insurance and coverage programs, and through the health insurance marketplace, financed by the States and the Federal Government of the United States. Revenues break down by activity as follows:
- Health care services within the Medicaid program (76.5%): services for low-income individuals, families and people with disabilities;
- health care services within the Medicare program (12.1%): services for the elderly and people with certain diseases, covered by the Medicare health insurance program;
- operating a health insurance marketplace (11.1%; Marketplace): a platform for offering health insurance plans, and allowing members of the Medicaid program, whose rising incomes have taken them out of eligibility, to purchase federally subsidized health insurance policies. The group also offers virtual care services;
- other (0.2%).
At the end of 2022, Molina Healthcare, Inc. had approximately 5.2 million members broken down by program between Medicaid (4.3 million members), Medicare (0.2 million) and Marketplace (0.7 million).
All revenues are generated in the United States.
Sector
Managed Healthcare
Calendar
2024-02-06
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
367USD
Average target price
364.25USD
Spread / Average Target
-0.75%
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.14% | 21 396 M $ | |
+3.79% | 509 B $ | |
-6.03% | 113 B $ | |
-22.20% | 75 432 M $ | |
-2.31% | 61 598 M $ | |
-8.54% | 40 070 M $ | |
+13.48% | 3 388 M $ | |
-34.01% | 1 467 M $ |